FDA Approves Wegovy to Lower Heart Attack and Stroke Risks

Key points

• The FDA has approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight.
• Clinical trials demonstrated a twenty percent reduction in major adverse cardiac events among participants taking the medication alongside standard care.
• The expanded indication is expected to improve insurance coverage arguments by framing the drug as a preventive cardiac treatment rather than a lifestyle weight loss product.
• Supply chain constraints are likely to persist as expanding eligibility increases nationwide demand for GLP-1 therapies.

This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.

Sources and methodology

Reported from the public datasets below.

• Bureau of Labor Statistics (BLS) - Consumer Price Index, food away from home
• Federal Reserve Economic Data (FRED) - Food services and drinking places series
• U.S. Census Bureau - Monthly Retail Trade, food services

All sources Foodie Pundit reports from

More from the Foodie Pundit Newsroom

• New York City Dining Scene Expands With Wave Of New Restaurant Openings This Week
• New York City Restaurant Industry Pipeline Expands With Wave Of Strategic Autumn Openings
• July Food Inflation Escalates to Three Year High as Grocery Bills Surge
• Three New Restaurants—Murano by Ferraro, The Wagyu House, and Oak Berry—Arrive in Fort Lauderdale
• Celebrity Chef Expansion Signals Major Culinary Shift in Arlington Entertainment District